Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
Nish Chaturvedi(Imperial College London), Anne Katrin Sjølie, Rudy Bilous(Barnsley Hospital), Ronald Klein(University of Wisconsin–Madison), Hans Henrik Parving(Copenhagen University Hospital), Trevor J. Orchard(University of Pittsburgh), John Fuller(The Royal Free Hospital), Massimo Porta(University of Turin)
Cited by 450
Related Papers
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
|The Lancet Global Health|2014|5.2k
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
Vascular Risk Factors and Diabetic Neuropathy
|New England Journal of Medicine|2005|1.3k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes
|New England Journal of Medicine|2009|790